GlassScriptPhysician profile
Xinqiang Han
NPI 1831287598
$31,585.90
in general payments reported to CMS, 2019-2025
28 companies · $504 in 2025
The $504 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $13K · 2021: $584 · 2022: $1,081 · 2023: $1,859 · 2024: $851 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Travel and Lodging: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.58 |
| Travel and Lodging | $879.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27,293.88 | 2019-2025 | Aveir, Confirm Rx, Amplatzer Amulet |
| Boston Scientific Corporation | $2,275.68 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Cardiofocus, INC. | $379.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $373.41 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $153.34 | 2020-2024 | Tagrisso, Farxiga, Wainua |
| Gilead Sciences, INC. | $135.68 | 2019 | |
| Amgen INC. | $125.55 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $123.25 | 2021-2025 | Winrevair, Verquvo |
| Pfizer INC. | $83.70 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $82.99 | 2019-2024 | |
| Novo Nordisk INC | $75.72 | 2023-2025 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $51.80 | 2021-2024 | Uptravi, Opsumit |
| Medtronic Vascular, INC. | $49.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.29 | 2019-2023 | Xarelto |
| Scpharmaceuticals INC. | $39.80 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $38.39 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $34.82 | 2021-2023 | Cleviprex, Kengreal |
| Lexicon Pharmaceuticals, INC. | $31.90 | 2023 | Inpefa |
| Altathera Pharmaceuticals LLC | $29.76 | 2023-2024 | Sotalol Hydrochloride |
| Kowa Pharmaceuticals America, INC. | $23.80 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.28 | 2024 | Arcalyst |
| Medtronic, INC. | $21.03 | 2025 | Symplicity G3 |
| Amarin Pharma, INC. | $18.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.88 | 2022 | |
| Philips North America LLC | $16.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.20 | 2020 | |
| Impulse Dynamics (USA) INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xinqiang Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.